TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Canaccord Genuity Group in a report released on Tuesday,Benzinga reports. They currently have a $104.00 price objective on the stock. Canaccord Genuity Group's target price points to a potential upside of 54.37% from the stock's previous close.
Several other equities analysts have also issued reports on TMDX. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Oppenheimer reaffirmed an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird cut their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. Piper Sandler dropped their target price on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research report on Wednesday, December 11th. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.
Check Out Our Latest Report on TransMedics Group
TransMedics Group Stock Performance
Shares of TransMedics Group stock opened at $67.37 on Tuesday. The firm has a 50 day simple moving average of $68.44 and a 200 day simple moving average of $96.43. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market cap of $2.27 billion, a P/E ratio of 71.85 and a beta of 2.12.
Institutional Trading of TransMedics Group
A number of institutional investors have recently modified their holdings of TMDX. Arizona State Retirement System lifted its stake in TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after acquiring an additional 184 shares in the last quarter. Venturi Wealth Management LLC lifted its position in shares of TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company's stock worth $136,000 after purchasing an additional 219 shares in the last quarter. National Bank of Canada FI boosted its holdings in TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after purchasing an additional 262 shares during the last quarter. Quarry LP grew its position in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company's stock valued at $76,000 after buying an additional 316 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
